SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026

SAB Biotherapeutics, Inc.

Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.
Completed equity financing up to $110M; expects cash with Tranche B warrant exercise to fund operations into 2026.
Phase 1 trial of SAB-142 for Type 1 diabetes on track for data by end of 2024.
Appointed Michael G. King Jr. as CFO; Andrew Moin and Katie Ellias added to board.
R&D expenses $16.5M (down from $36.4M); G&A $23.8M (up from $16.4M).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

SAB Biotherapeutics, Inc. reported the year and quarter ended December 31, 2023 results: net income net loss of $42.2 million.

Period: the year and quarter ended December 31, 2023
Net income: net loss of $42.2 million
Result: reported results

Exact text from the filing

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

View on SEC.gov

325 earnings releases filed in the last 30 days. Browse all earnings releases →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-038429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.